New Sarepta Therapeutic (SRPT) Data Supports Approval, Oppenheimer Says
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/30/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- McKesson reports cybersecurity incident affecting its information systems
- Mizuho is bullish on Broadcom ahead of Sept. 2 earnings, citing 30-quarter streak
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- BioNTech ends colorectal cancer mRNA therapy trial early
- Needham sees mature node semiconductor strength in latest tracker
Sarepta Therapeutics Announces Collaborative Research Agreement with Murdoch University Researchers Steve Wilton and Sue Fletcher
October 1, 2015 4:30 PM EDTCAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced a four year collaborative research agreement to establish the Sarepta Translational Laboratory with Murdoch University, Perth, Western Australia. The Laboratory, led by Murdoch University professors Steve Wilton, Ph.D. and Sue Fletcher, Ph.D., will explore the applicability of the Companys phosphorodiamidate morpholino oligomer (PMO) technology for disease targets beyond Duchenne muscular dystrophy (DMD), such as cystic fibrosis and spinal muscular atrophy.
The agreement provides the Murdoch University researchers with access to... More
Sarepta Therapeutics Announces Additional Long-Term Efficacy and Safety Data from Pivotal Phase IIb Program of Eteplirsen for Treatment of Duchenne Muscular Dystrophy
October 1, 2015 7:00 AM EDT-- Eteplirsen provided a statistically significant 6 minute walk test advantage of 151 meters at three years compared to an external control --
-- Fourth muscle biopsy results confirm increased dystrophin production in nearly all eteplirsen-treated patients and exon skipping in 100 percent of patients --
-- Eteplirsen safety profile remains consistent with prior results --
CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, Inc. (NASDAQ: SRPT), a developer of innovative RNA-targeted therapeutics, today announced additional clinical efficacy and safety data from the Companys... More
